^
    2years
    KRASG12C Inhibitor, VRTX126 in combination with Tyrosine Kinase Inhibitor, leads to pronounced and effective response in G12C-mutated cancers. (AACR-NCI-EORTC 2022)
    In vitro study using a combination matrix of VRTX126 and Afatinib indicated synergistic effect leading to a significant dose reduction of TKI which was further confirmed in in-vivo settings. This paves way for safely combining VRTX126 with multiple precision medicines, including TKIs at significantly lower doses. No
    Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase) • DUSP6 (Dual specificity phosphatase 6)
    |
    KRAS mutation
    |
    Gilotrif (afatinib) • VRTX126